Dr. Sunil Chandran Returns to Lead Technological Innovations at Amyris
September 2, 2025 - 19:36
Amyris, Inc. is excited to welcome back Dr. Sunil Chandran as its Chief Technology Officer. His return comes at a pivotal moment when the company is poised to enhance its capabilities in innovative and renewable biological chemistry. With a strong background in technology development and a proven track record in the industry, Dr. Chandran is expected to drive the company’s efforts to meet the increasing demand for sustainable solutions.
Dr. Chandran previously held the CTO position at Amyris and played a significant role in advancing the company’s technological framework. His expertise will be instrumental in guiding the research and development initiatives that align with the company's commitment to sustainability and innovation. As the market for renewable products continues to expand, his leadership is anticipated to accelerate the development of cutting-edge solutions that cater to customer needs.
The strategic appointment underscores Amyris's dedication to fostering advancements in biotechnology, ensuring that it remains at the forefront of the industry.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...